Veterinary Medicines

MILBEMAX 12.5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Authorised
  • Milbemycin oxime
  • Praziquantel
Download as PDF

Product identification

Medicine name:
MILBEMAX 12.5 MG/125 MG CHEWABLE TABLETS FOR DOGS
MILBEMAX (12,5+125)MG/TAB ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ
Active substance:
  • Milbemycin oxime
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    12.50
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    125.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Legal status of supply:
This information is not available for this product.
Authorisation status:
  • Valid
Authorised in:
  • Greece
Available in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Elanco GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Elanco France S.A.S
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 77258/30-10-2015/K-0157606
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0135/006
Concerned member states:
  • Austria
  • Belgium
  • Cyprus
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."